- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00474786
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)
28 de octubre de 2013 actualizado por: Pfizer
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
This is an international, randomized, open-label, outpatient, multicenter study.
Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID).
These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months.
Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
512
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Pfizer Investigational Site
-
Dresden, Alemania, 01307
- Pfizer Investigational Site
-
Heidelberg, Alemania, 69120
- Pfizer Investigational Site
-
Kassel, Alemania, 34125
- Pfizer Investigational Site
-
Luebeck, Alemania, 23538
- Pfizer Investigational Site
-
Muenchen, Alemania, 81675
- Pfizer Investigational Site
-
Neuss, Alemania, 41464
- Pfizer Investigational Site
-
Ulm, Alemania, 89081
- Pfizer Investigational Site
-
-
-
-
-
Buenos Aires, Argentina, C1437JCP
- Pfizer Investigational Site
-
Buenos Aires, Argentina, C1426ANZ
- Pfizer Investigational Site
-
Buenos Aires, Argentina, C1122AAL
- Pfizer Investigational Site
-
Nueva Cordoba, Argentina, X5006HBF
- Pfizer Investigational Site
-
Tucuman, Argentina, T4000 IAK
- Pfizer Investigational Site
-
-
Santa Fé
-
Rosario, Santa Fé, Argentina, S2000KZE
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Pfizer Investigational Site
-
St Leonards, New South Wales, Australia, 2065
- Pfizer Investigational Site
-
Westmead, New South Wales, Australia, 2145
- Pfizer Investigational Site
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Pfizer Investigational Site
-
Elizabeth Vale, South Australia, Australia, 5112
- Pfizer Investigational Site
-
Woodville South, South Australia, Australia, 5011
- Pfizer Investigational Site
-
-
-
-
-
Salzburg, Austria, 5020
- Pfizer Investigational Site
-
Wien, Austria, 1090
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Pfizer Investigational Site
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1Y 5L3
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- Pfizer Investigational Site
-
Victoria, British Columbia, Canadá, V8R 6V5
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 1V7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Canadá, B3H 3A7
- Pfizer Investigational Site
-
Halifax, Nova Scotia, Canadá, B3H 2Y9
- Pfizer Investigational Site
-
-
Ontario
-
Cornwall, Ontario, Canadá, K6R 5S5
- Pfizer Investigational Site
-
Hamilton, Ontario, Canadá, L8N 4A6
- Pfizer Investigational Site
-
London, Ontario, Canadá, N6A 4G5
- Pfizer Investigational Site
-
London, Ontario, Canadá, N6A 4L6
- Pfizer Investigational Site
-
Ottawa, Ontario, Canadá, K1H 8L6
- Pfizer Investigational Site
-
Ottawa, Ontario, Canadá, K1Y 4K7
- Pfizer Investigational Site
-
Toronto, Ontario, Canadá, M4N 3M5
- Pfizer Investigational Site
-
Toronto, Ontario, Canadá, M5G 2M9
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H3G 1A4
- Pfizer Investigational Site
-
-
-
-
Santiago
-
Providencia, Santiago, Chile
- Pfizer Investigational Site
-
-
-
-
-
Seoul, Corea, república de, 120-752
- Pfizer Investigational Site
-
Seoul, Corea, república de, 138-736
- Pfizer Investigational Site
-
Seoul, Corea, república de, 110-744
- Pfizer Investigational Site
-
Seoul, Corea, república de, 135-710
- Pfizer Investigational Site
-
-
-
-
-
Aarhus C, Dinamarca, 8000
- Pfizer Investigational Site
-
Herlev, Dinamarca, 2730
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, España, 08025
- Pfizer Investigational Site
-
Madrid, España, 28007
- Pfizer Investigational Site
-
Madrid, España, 28041
- Pfizer Investigational Site
-
Sevilla, España, 41013
- Pfizer Investigational Site
-
Valencia, España, 46010
- Pfizer Investigational Site
-
-
Asturias
-
Oviedo, Asturias, España, 33006
- Pfizer Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, España, 08916
- Pfizer Investigational Site
-
Sabadell, Barcelona, España, 08208
- Pfizer Investigational Site
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Pfizer Investigational Site
-
La Jolla, California, Estados Unidos, 92037
- Pfizer Investigational Site
-
La Jolla, California, Estados Unidos, 92093
- Pfizer Investigational Site
-
Los Angeles, California, Estados Unidos, 90095
- Pfizer Investigational Site
-
Los Angeles, California, Estados Unidos, 90095-6984
- Pfizer Investigational Site
-
Orange, California, Estados Unidos, 92868
- Pfizer Investigational Site
-
Riverside, California, Estados Unidos, 92505
- Pfizer Investigational Site
-
San Diego, California, Estados Unidos, 92103
- Pfizer Investigational Site
-
-
Connecticut
-
Meriden, Connecticut, Estados Unidos, 06451
- Pfizer Investigational Site
-
-
Indiana
-
Municie, Indiana, Estados Unidos, 47303
- Pfizer Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Pfizer Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Pfizer Investigational Site
-
Bethesda, Maryland, Estados Unidos, 20817
- Pfizer Investigational Site
-
-
Mississippi
-
Tupelo, Mississippi, Estados Unidos, 38801
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Estados Unidos, 74104
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78731
- Pfizer Investigational Site
-
Dallas, Texas, Estados Unidos, 75246
- Pfizer Investigational Site
-
Dallas, Texas, Estados Unidos, 75226
- Pfizer Investigational Site
-
San Antonio, Texas, Estados Unidos, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112-5550
- Pfizer Investigational Site
-
Salt Lake City, Utah, Estados Unidos, 84412
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Pfizer Investigational Site
-
-
-
-
-
Tampere, Finlandia, 33 521
- Pfizer Investigational Site
-
Turku, Finlandia, 20 520
- Pfizer Investigational Site
-
-
-
-
-
Angers, Francia, 49100
- Pfizer Investigational Site
-
Besancon, Francia, 25000
- Pfizer Investigational Site
-
Bordeaux, Francia, 33075
- Pfizer Investigational Site
-
Caen Cedex 05, Francia, 14076
- Pfizer Investigational Site
-
Clermont-Ferrand Cedex 1, Francia, 63011
- Pfizer Investigational Site
-
Dijon, Francia, 21079
- Pfizer Investigational Site
-
Lille, Francia, 59000
- Pfizer Investigational Site
-
Lyon Cedex 08, Francia, 69373
- Pfizer Investigational Site
-
Marseille Cedex 9, Francia, 13273
- Pfizer Investigational Site
-
Paris Cedex 15, Francia, 75908
- Pfizer Investigational Site
-
Poitiers Cedex, Francia, 86021
- Pfizer Investigational Site
-
Saint Herlain/Nantes Cedex, Francia, 44805
- Pfizer Investigational Site
-
Strasbourg, Francia, 67091
- Pfizer Investigational Site
-
Vandoeuvre Les Nancy, Francia, 54511
- Pfizer Investigational Site
-
Villejuif Cedex, Francia, 94805
- Pfizer Investigational Site
-
-
Cedex 5
-
Montpellier, Cedex 5, Francia, 34298
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungría, H-1122
- Pfizer Investigational Site
-
-
-
-
-
Chieti, Italia, 66013
- Pfizer Investigational Site
-
Firenze, Italia, 50134
- Pfizer Investigational Site
-
Napoli, Italia, 80131
- Pfizer Investigational Site
-
Pavia, Italia, 27100
- Pfizer Investigational Site
-
Roma, Italia, 00144
- Pfizer Investigational Site
-
Roma, Italia, 00152
- Pfizer Investigational Site
-
Roma, Italia, 0144
- Pfizer Investigational Site
-
-
-
-
-
Dordrecht, Países Bajos, 3318 AT
- Pfizer Investigational Site
-
Leeuwarden, Países Bajos, 8934 AD
- Pfizer Investigational Site
-
Zwolle, Países Bajos, 8025 AB
- Pfizer Investigational Site
-
-
-
-
-
Hong Kong, Porcelana
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Reino Unido, B15 2TH
- Pfizer Investigational Site
-
London, Reino Unido, SE1 9RT
- Pfizer Investigational Site
-
Manchester, Reino Unido, M23 9LT
- Pfizer Investigational Site
-
Newcastle upon Tyne, Reino Unido, NE4 6BE
- Pfizer Investigational Site
-
-
Birmingham
-
Edgbaston, Birmingham, Reino Unido, B5 7UG
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 0QQ
- Pfizer Investigational Site
-
-
Manchester
-
Withington, Manchester, Reino Unido, M20 4BX
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapur, 169610
- Pfizer Investigational Site
-
-
-
-
-
Göteborg, Suecia, SE-413 45
- Pfizer Investigational Site
-
Lund, Suecia, 221 85
- Pfizer Investigational Site
-
Malmo, Suecia, 205 02
- Pfizer Investigational Site
-
-
-
-
-
Basel, Suiza
- Pfizer Investigational Site
-
Bruderholz, Suiza
- Pfizer Investigational Site
-
Luzern, Suiza, 6000
- Pfizer Investigational Site
-
Rheinstrasse 26, Suiza
- Pfizer Investigational Site
-
-
BS
-
Basel, BS, Suiza, 4031
- Pfizer Investigational Site
-
-
Basel
-
Kleinriehenstrasse 30, Basel, Suiza
- Pfizer Investigational Site
-
-
GE
-
Geneva, GE, Suiza, 1221
- Pfizer Investigational Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).
- At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.
At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.
- More criteria apply
Exclusion Criteria:
- Metastatic CNS from RCC.
- Subjects who discontinued Sutent therapy due specifically to intolerance.
- Prior systemic therapy for mRCC other than sunitinib.
Active ketonuria, secondary to poorly controlled diabetes mellitus
- More criteria apply
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1
|
Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
|
|
Experimental: 2
|
Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly.
This infusion is to be administered over a 30-60 minute period.
Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Baseline up to 24 Months
|
Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first.
|
Baseline up to 24 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression Free Survival (PFS) by Investigator Assessment
Periodo de tiempo: Baseline up to 24 Months
|
Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first.
|
Baseline up to 24 Months
|
|
Percentage of Participants With Tumor Response
Periodo de tiempo: Baseline up to 24 Months
|
Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review.
CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response.
PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
|
Baseline up to 24 Months
|
|
Overall Survival (OS)
Periodo de tiempo: Baseline to date of death from any cause (up to 24 months)
|
Overall survival was the duration from randomization to death.
For participants who are alive, overall survival was censored at the last contact.
|
Baseline to date of death from any cause (up to 24 months)
|
|
Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment
Periodo de tiempo: Weeks 12, 24, and 36
|
PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first.
PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7.
|
Weeks 12, 24, and 36
|
|
Duration of Response (DR)
Periodo de tiempo: Baseline up to 24 Months
|
Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented.
Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method.
|
Baseline up to 24 Months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Baseline up to 24 months
|
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose.
Relatedness to [study drug] was assessed by the investigator (Yes/No).
Participants with multiple occurrences of an AE within a category were counted once within the category.
|
Baseline up to 24 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
- Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
- Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de septiembre de 2007
Finalización primaria (Actual)
1 de enero de 2012
Finalización del estudio (Actual)
1 de enero de 2013
Fechas de registro del estudio
Enviado por primera vez
15 de mayo de 2007
Primero enviado que cumplió con los criterios de control de calidad
15 de mayo de 2007
Publicado por primera vez (Estimar)
17 de mayo de 2007
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
21 de noviembre de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
28 de octubre de 2013
Última verificación
1 de octubre de 2013
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades Renales
- Enfermedades urológicas
- Adenocarcinoma
- Neoplasias Glandulares y Epiteliales
- Neoplasias Renales
- Carcinoma De Célula Renal
- Carcinoma
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Inhibidores de enzimas
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antibacterianos
- Inhibidores de la proteína quinasa
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Sorafenib
- Sirolimus
Otros números de identificación del estudio
- 3066K1-404
- B1771003
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .